C S Arun1, R Pandit, R Taylor. 1. Department of Medicine, The Medical School, University of Newcastle, Newcastle Upon Tyne, UK. csarun2003@yahoo.co.uk
Abstract
AIMS/HYPOTHESIS: Universal worsening of retinopathy after starting insulin therapy in Type 2 diabetes has been suggested in previous work. METHODS: We studied 294 such patients for up to 5 years to evaluate retinal changes and define the factors affecting progression of retinopathy. Yearly retinal photographs were graded using the EURODIAB system. RESULTS: Prior to insulin therapy, 26.2% (77/294) of the patients had minimal non-proliferative diabetic retinopathy (NPDR), 3.7% (n=11) had moderate NPDR and 1% (n=3) had severe NPDR. Over the first 3 years of insulin therapy, significant progression occurred in 36 subjects (12.6%). This comprised 5/193 (2.6%) without any retinopathy at baseline, 22/77 (28.5%) with minimal NPDR and 6/11 with moderate NPDR (54.5%) (chi2=56.1, p<0.001). In a control group of 70 patients who remained on oral hypoglycaemic agents, nine patients had significant worsening of retinopathy over 3 years. Over 5 years, 22/127 (17.3%) of patients (9/95 without and 13/32 with retinopathy at baseline [chi2=16.2, p<0.001]) had significant progression of retinopathy. Higher baseline HbA1c (p=0.002) and lower initial decrease in HbA1c (p=0.007) were each independent predictors of greater retinopathy progression over this period. There was no significant worsening of visual acuity in patients whose retinopathy progressed. CONCLUSIONS/ INTERPRETATION: After initiation of insulin treatment in Type 2 diabetes, clinically significant worsening of retinopathy over a 3-year period was uncommon in those with no retinopathy (2.6%) but occurred in 31.8% of patients with any retinopathy at baseline. The risk of serious worsening of retinopathy after insulin therapy is started in all patients with Type 2 diabetes may have been previously overestimated.
AIMS/HYPOTHESIS: Universal worsening of retinopathy after starting insulin therapy in Type 2 diabetes has been suggested in previous work. METHODS: We studied 294 such patients for up to 5 years to evaluate retinal changes and define the factors affecting progression of retinopathy. Yearly retinal photographs were graded using the EURODIAB system. RESULTS: Prior to insulin therapy, 26.2% (77/294) of the patients had minimal non-proliferative diabetic retinopathy (NPDR), 3.7% (n=11) had moderate NPDR and 1% (n=3) had severe NPDR. Over the first 3 years of insulin therapy, significant progression occurred in 36 subjects (12.6%). This comprised 5/193 (2.6%) without any retinopathy at baseline, 22/77 (28.5%) with minimal NPDR and 6/11 with moderate NPDR (54.5%) (chi2=56.1, p<0.001). In a control group of 70 patients who remained on oral hypoglycaemic agents, nine patients had significant worsening of retinopathy over 3 years. Over 5 years, 22/127 (17.3%) of patients (9/95 without and 13/32 with retinopathy at baseline [chi2=16.2, p<0.001]) had significant progression of retinopathy. Higher baseline HbA1c (p=0.002) and lower initial decrease in HbA1c (p=0.007) were each independent predictors of greater retinopathy progression over this period. There was no significant worsening of visual acuity in patients whose retinopathy progressed. CONCLUSIONS/ INTERPRETATION: After initiation of insulin treatment in Type 2 diabetes, clinically significant worsening of retinopathy over a 3-year period was uncommon in those with no retinopathy (2.6%) but occurred in 31.8% of patients with any retinopathy at baseline. The risk of serious worsening of retinopathy after insulin therapy is started in all patients with Type 2 diabetes may have been previously overestimated.
Authors: N Chaturvedi; A K Sjoelie; M Porta; S J Aldington; J H Fuller; M Songini; E M Kohner Journal: Diabetes Care Date: 2001-02 Impact factor: 19.112
Authors: Matthew C Riddle; William T Cefalu; Philip H Evans; Hertzel C Gerstein; Michael A Nauck; William K Oh; Amy E Rothberg; Carel W le Roux; Francesco Rubino; Philip Schauer; Roy Taylor; Douglas Twenefour Journal: Diabetologia Date: 2021-08-30 Impact factor: 10.122
Authors: Matthew C Riddle; William T Cefalu; Philip H Evans; Hertzel C Gerstein; Michael A Nauck; William K Oh; Amy E Rothberg; Carel W le Roux; Francesco Rubino; Philip Schauer; Roy Taylor; Douglas Twenefour Journal: J Clin Endocrinol Metab Date: 2022-01-01 Impact factor: 6.134
Authors: Tiansheng Wang; Jin-Liern Hong; Emily W Gower; Virginia Pate; Seema Garg; John B Buse; Til Stürmer Journal: Diabetes Care Date: 2018-07-16 Impact factor: 19.112
Authors: Yiyuan Liu; Minghui Wang; Andrew D Morris; Alex S F Doney; Graham P Leese; Ewan R Pearson; Colin N A Palmer Journal: Diabetes Care Date: 2013-10-29 Impact factor: 19.112
Authors: Elizabeth Morris; Paul Aveyard; Pamela Dyson; Michaela Noreik; Clare Bailey; Robin Fox; Derek Jerome; Garry D Tan; Susan A Jebb Journal: Diabetes Obes Metab Date: 2019-11-25 Impact factor: 6.408